US2856415A
(en)
|
1957-11-13 |
1958-10-14 |
Searle & Co |
3,19-dihydroxy-5-androstene derivatives
|
FR1380417A
(fr)
|
1962-05-15 |
1964-12-04 |
Roussel Uclaf |
Nouveaux androstanyl-pyrazoles et procédé de préparation
|
US3206459A
(en)
|
1962-10-19 |
1965-09-14 |
Syntex Corp |
10alpha-pregnan-19-ol derivatives
|
US3169134A
(en)
|
1963-03-21 |
1965-02-09 |
Searle & Co |
2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
|
BE754111A
(fr)
|
1969-07-29 |
1971-01-29 |
Upjohn Co |
Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
|
GB1434919A
(en)
|
1972-06-15 |
1976-05-12 |
Glaxo Lab Ltd |
3alpha-hydroxy androstanes
|
US3953429A
(en)
*
|
1970-12-17 |
1976-04-27 |
Glaxo Laboratories Limited |
Anaesthetic steroids of the androstance and pregnane series
|
US3943124A
(en)
|
1970-12-17 |
1976-03-09 |
Gordon Hanley Phillipps |
Chemical compounds
|
GB1380246A
(en)
|
1970-12-17 |
1975-01-08 |
Glaxo Lab Ltd |
3alpha-hydroxy-androstanes and esters thereof
|
US3983111A
(en)
|
1972-05-05 |
1976-09-28 |
Glaxo Laboratories Limited |
Steroidal anaesthetics of the pregnane and 19-norpregnane series
|
GB1430942A
(en)
|
1972-05-05 |
1976-04-07 |
Glaxo Lab Ltd |
21-substituted 3alpha-hydroxy pregnanes
|
GB1436324A
(en)
*
|
1972-05-12 |
1976-05-19 |
Glaxo Lab Ltd |
Anaesthetic 3alpha-hydroxy pregnanes
|
ES432106A1
(es)
|
1973-11-30 |
1976-11-01 |
Schering Ag |
Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
|
US4071625A
(en)
|
1974-05-13 |
1978-01-31 |
Richardson-Merrell Inc. |
19-Oxygenated-5α-androstanes for the enhancement of libido
|
DE2438020A1
(de)
|
1974-08-05 |
1976-02-26 |
Schering Ag |
18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
|
IL48628A0
(en)
|
1974-12-23 |
1976-02-29 |
Schering Ag |
D-homo-20-keto-pregnanes and process for their manufactur
|
DE2526373C2
(de)
|
1975-06-11 |
1983-11-10 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden
|
GB1570394A
(en)
|
1976-01-06 |
1980-07-02 |
Glaxo Lab Ltd |
11-acyloxy-3-hydroxy steroids
|
US4192871A
(en)
|
1976-01-06 |
1980-03-11 |
Glaxo Laboratories Limited |
Chemical compounds
|
GB1581234A
(en)
*
|
1976-04-05 |
1980-12-10 |
Glaxo Operations Ltd |
11a - amino - 3a - hydroxysteroids
|
DE2632677A1
(de)
|
1976-07-16 |
1978-01-26 |
Schering Ag |
Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung
|
GB1581235A
(en)
|
1977-04-04 |
1980-12-10 |
Glaxo Operations Ltd |
11a-amino-3a-hydroxy-steroids
|
US4389345A
(en)
|
1981-10-09 |
1983-06-21 |
G.D. Searle & Co. |
3-Oxoestra-17-acetonitrile and unsaturated analogs
|
US4495102A
(en)
|
1982-09-03 |
1985-01-22 |
G. D. Searle & Co. |
Aminoalkyl steroids
|
US5232917A
(en)
|
1987-08-25 |
1993-08-03 |
University Of Southern California |
Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
|
US5120723A
(en)
|
1987-08-25 |
1992-06-09 |
University Of Southern California |
Method, compositions, and compounds for modulating brain excitability
|
US5319115A
(en)
|
1987-08-25 |
1994-06-07 |
Cocensys Inc. |
Method for making 3α-hydroxy, 3β-substituted-pregnanes
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
CA2118938A1
(fr)
|
1991-09-13 |
1993-04-01 |
Kelvin W. Gee |
Recepteur a gaba-a avec sites de fixation pour steroides
|
DE4232681C2
(de)
|
1992-09-29 |
1994-11-24 |
Sigma Tau Ind Farmaceuti |
17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
|
AU698834B2
(en)
|
1993-05-24 |
1998-11-12 |
Purdue Pharma Ltd. |
Methods and compositions for inducing sleep
|
CZ300694A3
(en)
|
1993-12-02 |
1996-05-15 |
Akzo Nobel Nv |
Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
|
EP0656365B1
(fr)
|
1993-12-02 |
1997-04-09 |
Akzo Nobel N.V. |
Dérivés 2-bêta-morpholino de androstane
|
ATE195654T1
(de)
*
|
1994-02-14 |
2000-09-15 |
Euro Celtique Sa |
Androstane und pregnane zur allosterischen modulation des gaba-rezeptors
|
US5939545A
(en)
|
1994-02-14 |
1999-08-17 |
Cocensys, Inc. |
Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
|
JP2002500616A
(ja)
|
1994-07-21 |
2002-01-08 |
ファルマシア・アンド・アップジョン・カンパニー |
神経学的に活性なアミノステロイド
|
ATE198753T1
(de)
|
1994-11-23 |
2001-02-15 |
Cocensys Inc |
Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors
|
BR9608592A
(pt)
|
1995-06-06 |
1999-06-29 |
Cocensys Inc |
Esteróides neuroativos da série do androstano e do pregnano
|
AU3967297A
(en)
*
|
1996-08-01 |
1998-02-25 |
Cocensys, Inc. |
Use of gaba and nmda receptor ligands for the treatment of migraine headache
|
US5994334A
(en)
|
1997-02-05 |
1999-11-30 |
University Of Maryland |
Androgen synthesis inhibitors
|
US5935545A
(en)
|
1997-07-11 |
1999-08-10 |
E. I. Du Pont De Nemours And Company |
Process for producing an aqueous solution comprising ferric chloride
|
AU756001B2
(en)
*
|
1998-03-11 |
2003-01-02 |
Umecrine Mood Ab |
Epiallopregnanolone in the treatment of CNS disorders
|
CZ20013867A3
(cs)
|
1999-04-29 |
2002-07-17 |
Purdue Pharma Ltd. |
3alfa-hydroxy-3beta-methoxymethyl-21-heterocyklem substituované steroidy s anestetickým účinkem
|
US7018406B2
(en)
|
1999-11-17 |
2006-03-28 |
Corevalve Sa |
Prosthetic valve for transluminal delivery
|
ES2243442T3
(es)
|
2000-02-18 |
2005-12-01 |
Taiho Pharmaceutical Company Limited |
Procedimiento de preparacion de derivados esteroides.
|
US6855836B2
(en)
|
2000-10-26 |
2005-02-15 |
Jenapharm Gmbh & Co. Kg |
17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds
|
AU2002232509A1
(en)
|
2000-11-03 |
2002-05-15 |
Washington University |
Estrone-derivatives having cytoprotective activity
|
GR1003861B
(el)
|
2000-12-29 |
2002-04-11 |
|
Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
|
JP4719144B2
(ja)
|
2003-03-24 |
2011-07-06 |
ステリックス リミテッド |
ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体
|
CA2527019A1
(fr)
|
2003-05-29 |
2005-01-06 |
Washington University |
13,24-cyclo-18,21-dinorcholanes neuroactifs et steroides pentacycliques structurellement associes
|
EP1689767A1
(fr)
|
2003-11-24 |
2006-08-16 |
Merck & Co., Inc. |
Modulateurs des recepteurs estrogeniques
|
WO2005105822A2
(fr)
|
2004-04-23 |
2005-11-10 |
Euro-Celtique S.A. |
Procede de fabrication de steroides 3-alpha-hydroxy sustitues, nouveaux derives de steroides et leurs applications
|
US8604011B2
(en)
|
2004-09-27 |
2013-12-10 |
The Regents Of The University Of California |
Therapy for treatment of chronic degenerative brain diseases and nervous system injury
|
US20070014719A1
(en)
|
2004-09-29 |
2007-01-18 |
Reading Christopher L |
Steroid analogs and characterization and treatment methods
|
PL2168585T3
(pl)
|
2005-06-09 |
2012-05-31 |
Euro Celtique Sa |
Kompozycje farmaceutyczne steroidów neuroaktywnych i ich zastosowania
|
EP2097437B1
(fr)
*
|
2006-11-21 |
2015-05-27 |
Umecrine Cognition AB |
Utilisation de stéroïdes dérivés du prégnane et de l'androstane pour la fabrication d'une composition pharmaceutique pour le traitement de troubles du snc
|
US20090203658A1
(en)
|
2007-01-08 |
2009-08-13 |
Duke University |
Neuroactive steroid compositions and methods of use therefor
|
DE102007027636A1
(de)
|
2007-06-12 |
2008-12-18 |
Bayer Schering Pharma Aktiengesellschaft |
17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
|
WO2008157460A1
(fr)
|
2007-06-15 |
2008-12-24 |
Cook, Kevin, M. |
Steroides d'androstane et de pregnane presentant de puissantes proprietes de modulation allosterique du complexe recepteur gaba/ionophore chlorure
|
GB0711948D0
(en)
|
2007-06-20 |
2007-08-01 |
Bionature E A Ltd |
Neurosteriod compounds
|
CN101412742B
(zh)
|
2007-10-19 |
2013-07-31 |
天津金耀集团有限公司 |
一种抑制血管新生的硝酸酯药物
|
US20090264443A1
(en)
|
2008-04-18 |
2009-10-22 |
David Helton |
Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
|
CN101624414B
(zh)
|
2008-07-07 |
2013-02-13 |
天津金耀集团有限公司 |
一种抑制血管新生的硝酸酯药物
|
CZ2008434A3
(cs)
|
2008-07-10 |
2009-12-09 |
Ústav organické chemie a biochemie Akademie ved CR, v. v. i. |
Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
|
WO2010054158A2
(fr)
|
2008-11-07 |
2010-05-14 |
Auspex Pharmaceuticals, Inc. |
Modulateurs stéroïdiens du récepteur des glucocorticoïdes
|
US20110152840A1
(en)
|
2009-12-23 |
2011-06-23 |
Drugtech Corporation |
Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
|
US20130303500A1
(en)
|
2010-07-30 |
2013-11-14 |
Medexis S.A. |
Compounds and methods for treating neoplasia
|
WO2012083090A2
(fr)
|
2010-12-15 |
2012-06-21 |
Harbor Biosciences, Inc. |
Procédés et composés utilisés pour préparer des stéroïdes 3 alpha-oxygène substitués
|
WO2012109752A1
(fr)
|
2011-02-15 |
2012-08-23 |
Socpra Sciences Et Génie, S.E.C. |
Alcaloïdes stéroïdiens et leurs utilisations en tant qu'agents antimicrobiens contre les micro-organismes à défaut de transport d'électrons et en tant qu'exhausteurs d'agents microbiens contre des bactéries pathogènes
|
CZ303443B6
(cs)
|
2011-02-15 |
2012-09-12 |
Ústav organické chemie a biochemie Akademie ved CR, v.v.i. |
Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
|
WO2012116290A2
(fr)
|
2011-02-25 |
2012-08-30 |
Washington University |
Stéroïdes neuroactifs substitués par 17(20)-z-vinylcyano, promédicaments de ceux-ci et procédés de traitement les utilisant
|
ES2657986T3
(es)
|
2011-03-23 |
2018-03-07 |
Etsuro Ito |
Método y kit para la medición de muy alta sensibilidad de proteína y ácido nucleico y un novedoso sustrato enzimático
|
CA2843436A1
(fr)
|
2011-07-29 |
2013-02-07 |
The Regents Of The University Of California |
Nouveaux steroides substitues en 17? par un heteroaryle, capables de moduler les recepteurs gabaa
|
US20150158903A1
(en)
|
2011-09-08 |
2015-06-11 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
CA2852057C
(fr)
|
2011-10-14 |
2022-06-07 |
Sage Therapeutics, Inc. |
Composes 19-nor-pregnane 3,3-disubstituees, compositions et utilisationsassociees dans le traitement de troubles associes au snc
|
BR112014018110B1
(pt)
|
2012-01-23 |
2022-06-07 |
Sage Therapeutics, Inc |
Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina
|
WO2013188792A2
(fr)
|
2012-06-15 |
2013-12-19 |
Sage Therapeutics, Inc. |
Stéroïdes neuroactifs, compositions, et leurs utilisations
|
DK3336097T3
(da)
|
2012-06-19 |
2020-09-28 |
Intercept Pharmaceuticals Inc |
Fremstilling af ikke-krystallinsk obeticholsyre
|
US20140050789A1
(en)
|
2012-08-13 |
2014-02-20 |
The Regents Of The University Of California |
Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
|
KR102305359B1
(ko)
|
2012-08-21 |
2021-09-24 |
세이지 테라퓨틱스, 인크. |
간질 또는 간질지속 상태를 치료하는 방법
|
WO2014058736A1
(fr)
|
2012-10-08 |
2014-04-17 |
Washington University |
Stéroïdes neuroactifs 19-alcoxy-17(20)-z-vinylcyano-substitués, promédicaments associés et méthodes de traitement les utilisant
|
WO2014071449A1
(fr)
|
2012-11-09 |
2014-05-15 |
Goodchild Investments Pty Ltd |
Stéroïdes neuroactifs et leur utilisation pour faciliter la neuroprotection
|
CA2892811A1
(fr)
|
2012-11-30 |
2014-06-05 |
The Regents Of The University Of California |
Allopregnanolone et sel de sulfobutylether-?-cyclodextrine pour le traitement de la depression post-partum
|
BR112015014397B1
(pt)
|
2012-12-18 |
2021-02-02 |
Washington University |
composto, composição farmacêutica e uso de um composto
|
US8939545B2
(en)
|
2012-12-20 |
2015-01-27 |
Eastman Kodak Company |
Inkjet printing with managed airflow for condensation control
|
WO2014108808A2
(fr)
|
2013-01-09 |
2014-07-17 |
Henry James Lorne |
Formulations pharmaceutiques pour le traitement et la prévention de la neuropathologie et de la neurodégénérescence induites par un traumatisme
|
CA2831054C
(fr)
|
2013-01-09 |
2016-08-30 |
Sapna Life Sciences Corp. |
Formulations et procedes pour leur utilisation dans le traitement d'une neuropathologie et d'une neurodegeneration en raison d'une lesion traumatique
|
GB201302368D0
(en)
|
2013-02-11 |
2013-03-27 |
Univ Bath |
Compound
|
US9512170B2
(en)
|
2013-03-01 |
2016-12-06 |
Washington University |
Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
|
US9562026B2
(en)
|
2013-03-14 |
2017-02-07 |
Washington University |
Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
|
US9725481B2
(en)
|
2013-04-17 |
2017-08-08 |
Sage Therapeutics, Inc. |
19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
|
SG10201802389SA
(en)
|
2013-04-17 |
2018-04-27 |
Sage Therapeutics Inc |
19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
|
LT2986624T
(lt)
|
2013-04-17 |
2020-07-10 |
Sage Therapeutics, Inc. |
Neuroaktyvūs 9-nor steroidai, skirti gydymo metodams
|
US20160068563A1
(en)
|
2013-04-17 |
2016-03-10 |
Boyd L. Harrison |
19-nor neuroactive steroids and methods of use thereof
|
AU2014290400B2
(en)
|
2013-07-19 |
2019-12-05 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
PT3035940T
(pt)
|
2013-08-23 |
2019-01-28 |
Sage Therapeutics Inc |
Esteroides neuroativos, composições e seus usos
|
PL3705488T3
(pl)
|
2014-05-29 |
2022-12-05 |
Sage Therapeutics, Inc. |
Sterydy neuroaktywne, kompozycje i ich zastosowania
|
US10246482B2
(en)
|
2014-06-18 |
2019-04-02 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
US10172870B2
(en)
|
2014-09-02 |
2019-01-08 |
The Texas A&M University System |
Method of treating organophosphate intoxication by administration of neurosteroids
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
EP3753927B1
(fr)
|
2014-10-16 |
2023-07-19 |
Sage Therapeutics, Inc. |
Compositions et méthodes pour traiter des troubles du snc
|
KR102612943B1
(ko)
|
2014-10-16 |
2023-12-13 |
세이지 테라퓨틱스, 인크. |
Cns 장애의 치료를 위한 조성물 및 방법
|
PT3224269T
(pt)
|
2014-11-27 |
2020-06-01 |
Sage Therapeutics Inc |
Composições e métodos para tratamento de distúrbios do snc
|
SI3250210T1
(sl)
|
2015-01-26 |
2021-07-30 |
Sage Therapeutics, Inc. |
Sestavki in metode za zdravljenje CNS motenj
|
CN105985396A
(zh)
|
2015-02-16 |
2016-10-05 |
苏州泽璟生物制药有限公司 |
氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
|
US10329320B2
(en)
|
2015-02-20 |
2019-06-25 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
WO2016164763A1
(fr)
|
2015-04-10 |
2016-10-13 |
Sage Therapeutics, Inc. |
Compositions et méthodes permettant de traiter des troubles du snc
|
MA45276A
(fr)
|
2015-06-18 |
2018-04-25 |
Sage Therapeutics Inc |
Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
|
UY36741A
(es)
|
2015-06-21 |
2016-12-30 |
Prevacus Inc |
Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
|
EP3347368A4
(fr)
|
2015-09-08 |
2019-01-23 |
Viewpoint Therapeutics, Inc. |
Composés et formulations pour traiter les maladies ophthalmiques
|
JP2018530585A
(ja)
|
2015-10-16 |
2018-10-18 |
マリナス ファーマシューティカルズ インコーポレイテッド |
ナノ粒子を含む注射可能な神経ステロイド製剤
|
US20200306262A1
(en)
|
2015-11-20 |
2020-10-01 |
Sage Therapeutics, Inc. |
Compounds and methods of their use
|
CN109414444A
(zh)
|
2016-03-08 |
2019-03-01 |
萨奇治疗股份有限公司 |
神经活性类固醇、其组合物及用途
|
US10226550B2
(en)
|
2016-03-11 |
2019-03-12 |
Brigham Young University |
Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
|
US20190233465A1
(en)
|
2016-07-11 |
2019-08-01 |
Sage Therapeutics, Inc. |
C7, c12, and c16 substituted neuroactive steroids and their methods of use
|
EP4302764A2
(fr)
|
2016-07-11 |
2024-01-10 |
Sage Therapeutics, Inc. |
Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
|
CN115974954A
(zh)
|
2016-08-23 |
2023-04-18 |
萨奇治疗股份有限公司 |
19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
CN108727453A
(zh)
|
2017-04-20 |
2018-11-02 |
华东理工大学 |
新型pd-1抑制剂及其应用
|
WO2019018119A1
(fr)
|
2017-07-18 |
2019-01-24 |
Pairnomix, Llc |
Méthodes de traitement de l'épilepsie et d'affections associées à kcnti
|
CN116370475A
(zh)
|
2017-08-31 |
2023-07-04 |
武田药品工业株式会社 |
中枢神经***病症的治疗
|
TW202342058A
(zh)
|
2017-09-07 |
2023-11-01 |
美商賽吉醫療公司 |
神經活性類固醇及其使用方法
|
US20200276209A1
(en)
|
2017-09-11 |
2020-09-03 |
Sage Therapeutics, Inc. |
Methods of treating epilepsy or status epilepticus
|
TW202339764A
(zh)
|
2017-09-14 |
2023-10-16 |
美商賽吉醫療公司 |
19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法
|
SG11202004329TA
(en)
|
2017-11-10 |
2020-06-29 |
Marinus Pharmaceuticals Inc |
Ganaxolone for use in treating genetic epileptic disoders
|
MA51046A
(fr)
|
2017-12-08 |
2021-03-17 |
Sage Therapeutics Inc |
Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
|
US20210101928A1
(en)
|
2017-12-22 |
2021-04-08 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
KR20200104349A
(ko)
|
2017-12-22 |
2020-09-03 |
세이지 테라퓨틱스, 인크. |
Cns 장애의 치료를 위한 조성물 및 방법
|
WO2019140272A1
(fr)
|
2018-01-12 |
2019-07-18 |
Sage Therapeutics, Inc. |
Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
|
US20210338692A1
(en)
|
2018-06-12 |
2021-11-04 |
Sage Therapeutics, Inc. |
A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
|
EP3864022B1
(fr)
|
2018-10-12 |
2023-09-20 |
Sage Therapeutics, Inc. |
Stéroïdes neuroactifs substitués en position 10 avec un groupe cyclique pour une utilisation dans le traitement de troubles du système nerveux central
|
US20210363175A1
(en)
|
2018-10-19 |
2021-11-25 |
Sage Therapeutics, Inc. |
9(11)-unsaturated neuroactive steroids and their methods of use
|
US20230322846A9
(en)
|
2018-12-05 |
2023-10-12 |
Sage Therapeutics, Inc. |
Neuroactive steroids and their methods of use
|
BR112021012242A2
(pt)
|
2018-12-21 |
2021-09-28 |
Sage Therapeutics, Inc. |
Esteroides neuroativos de 3-alfa-hidróxi-17-beta-amida e composições destes
|
TW202110824A
(zh)
|
2019-05-24 |
2021-03-16 |
美商賽吉醫療公司 |
化合物、組合物及使用方法
|
MX2021014515A
(es)
|
2019-05-31 |
2022-03-22 |
Sage Therapeutics Inc |
Esteroides neuroactivos y composiciones de estos.
|
MX2021015942A
(es)
|
2019-06-27 |
2022-04-18 |
Sage Therapeutics Inc |
Composiciones y métodos para tratar trastornos del snc.
|
EP3990467A1
(fr)
|
2019-06-27 |
2022-05-04 |
Sage Therapeutics, Inc. |
Compositions et méthodes de traitement de troubles du système nerveux central
|
BR112021026445A2
(pt)
|
2019-06-27 |
2022-03-08 |
Sage Therapeutics Inc |
Composições e métodos para tratar distúrbios de cns
|
JP2023504517A
(ja)
|
2019-12-05 |
2023-02-03 |
セージ セラピューティクス, インコーポレイテッド |
19-ノルc3,3-二置換c21-n-ピラゾリルステロイドおよびその使用方法
|
JP2023518411A
(ja)
|
2020-03-18 |
2023-05-01 |
セージ セラピューティクス, インコーポレイテッド |
神経刺激性ステロイド及びその使用方法
|
IL296645A
(en)
|
2020-03-25 |
2022-11-01 |
Sage Therapeutics Inc |
Use of substances to treat respiratory conditions
|
MX2022016343A
(es)
|
2020-06-24 |
2023-03-06 |
Sage Therapeutics Inc |
Esteroides neuroactivos y composiciones de estos.
|
US20230285417A1
(en)
|
2020-07-20 |
2023-09-14 |
Sage Therapeutics, Inc. |
Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
|
KR20230124916A
(ko)
|
2020-11-25 |
2023-08-28 |
세이지 테라퓨틱스, 인크. |
Cns 장애를 치료하기 위한 조성물 및 방법
|
KR20230136599A
(ko)
|
2021-01-28 |
2023-09-26 |
세이지 테라퓨틱스, 인크. |
성 기능장애의 치료를 위한 신경활성 스테로이드의용도
|
WO2022177718A1
(fr)
|
2021-02-18 |
2022-08-25 |
Sage Therapeutics, Inc. |
Utilisation d'un stéroïde neuroactif pour le traitement d'un dysfonctionnement sexuel
|
TW202300156A
(zh)
|
2021-03-17 |
2023-01-01 |
美商賽吉醫療公司 |
用於治療重度憂鬱症之19-nor-c3,3-二取代c21-n-吡唑基類固醇
|
BR112023021131A2
(pt)
|
2021-04-12 |
2023-12-19 |
Sage Therapeutics Inc |
Tratamento de tremor essencial
|
EP4329770A1
(fr)
|
2021-04-29 |
2024-03-06 |
Sage Therapeutics, Inc. |
Stéroïde c21-n-pyrazolyl disubstitué en c3,3 19-nor destiné à être utilisé dans le traitement de la dépression majeure et de la dépression post-partum
|
AU2022267304A1
(en)
|
2021-04-29 |
2023-11-02 |
Sage Therapeutics, Inc. |
Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female
|